Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia
NCT ID: NCT00934986
Last Updated: 2011-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2008-03-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The involvement of Natural Killer cells (NK) in the efficiency of the treatment in lymphoma and the beginning of new therapies based on function and activation of NK, justify an improvement of knowledge about the status of the population of NK (number, function, genic expression) in Chronic Lymphocytic Leukemia (CLL).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
NCT06475469
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
NCT00019032
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
NCT02902874
Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00058396
International Extranodal NK/T-cell Lymphoma Project
NCT02386813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective:
Evaluation of the expression and function of receptors activator of NK cell (KIRs) in patients with CLL at stage A with therapeutic abstention, or stage B or C which require a treatment.
Secondary objectives:
Measure of the evolution of cytotoxic function of NK cells and theirs biomarkers of activation when the patient receives an immunochemotherapy with Rituximab/ Fludarabine/ Cyclophosphamide (RCF).
Verification, by analysis, of functions and biomarkers of the adaptive and innate immunity
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surface expression of functional biomarkers of the NK cell
An extra blood sample of 40 ml is required :
* Stage A patient who does not require a treatment: one sample the day of enrollment.
* Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who can undergo blood collection
* Patient aged 18 years and older
* Signed consent
* Patient with anemia: haemoglobin \< 9 g/dl
* Pregnancy, breast feeding
* Patient in an urgent situation, or unable to give a consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Paoli-Calmettes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thérèse AURRAN-SCHLEINITZ, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Paoli-Calmettes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut PAOLI-CALMETTES
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Official web site of the sponsor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LLC-NK/IPC 2007-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.